Xilio Therapeutics (XLO) Non-Current Assets (2020 - 2026)

Xilio Therapeutics has disclosed Non-Current Assets across 7 years of filings, most recently posting $8.8 million for Q2 2026.

• In Q2 2026, Non-Current Assets fell 12.98% year-over-year to $8.8 million; the TTM figure through Jun 2026 stood at $37.3 million (down 12.79% YoY), while the FY2025 annual figure was $9.7 million, down 10.91% from the prior year.
• Non-Current Assets came in at $8.8 million for Q2 2026 at Xilio Therapeutics, down from $9.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $15.3 million in Q1 2022 to a low of $8.8 million in Q2 2026.
• Average Non-Current Assets over 5 years is $12.2 million, with a median of $12.3 million recorded in 2023.
• Year-over-year, Non-Current Assets slipped 0.35% in 2022 and retreated 21.66% in 2025.
• Over 5 years, Non-Current Assets stood at $14.7 million in 2022, then retreated by 12.75% to $12.8 million in 2023, then fell by 15.3% to $10.8 million in 2024, then retreated by 10.91% to $9.7 million in 2025, then slipped by 9.03% to $8.8 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $8.8 million in Q2 2026, $9.3 million in Q1 2026, and $9.7 million in Q4 2025.